MedTrace Logo

An Exploratory Study of PQ Grass 27600 SU

NCT04687059 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 119

Last updated 2026-04-29

Study results available
· View outcomes & findings →

Summary

PQGrass309 is aimed at exploring the expected average treatment effect of PQ Grass 27600 SU cumulative dose on symptom and medication score in a field setting. The study will enrol adult subjects with seasonal allergic rhinitis and/or rhinoconjunctivitis (SAR) induced by grass pollen exposure.

Conditions

  • Rhinitis, Allergic, Seasonal

Interventions

BIOLOGICAL

PQ Grass

Suspension for injection

DRUG

Active Placebo

Suspension for injection

DRUG

Standard Placebo

Solution for injection

Sponsors & Collaborators

  • Allergy Therapeutics

    lead INDUSTRY

Principal Investigators

  • Pieter-Jan de Kam, Ph.D · Global R&D - Clinical Director

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-19
Primary Completion
2021-08-18
Completion
2021-10-28
FDA Drug
Yes

Countries

  • United States
  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04687059 on ClinicalTrials.gov